To determine the role of the TGF-β/Smad signalling pathway in the tumour-promoting effects of SGMS2, we specifically disrupted the TGF-β/Smad signalling pathway using pirfenidone in SGMS2 transient overexpression breast cancer cells. This evidence concerns the gene SGMS2 and breast cancer.